{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:50Z","timestamp":1786480310527,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 20K17261"],"award-info":[{"award-number":["JP 20K17261"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This is the first report to describe dose dependency in the effects of tolvaptan treatment for autosomal dominant polycystic kidney disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The weight-adjusted average daily dose of tolvaptan was found to be a factor that significantly affected the change in eGFR.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>If a patient shows tolerance, increasing the tolvaptan dose to the maximum should be considered.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0007342020","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T17:50:11Z","timestamp":1621360211000},"page":"1148-1151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.34067","volume":"2","author":[{"given":"Taro","family":"Akihisa","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Ushio","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Blood Purification, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Women\u2019s Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"B3-20250825","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s10557-011-6299-3","article-title":"Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: Results of single- and multiple-dose studies in healthy Japanese male volunteers","volume":"25","author":"Kim","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jclinepi.2014.12.014","article-title":"The number of subjects per variable required in linear regression analyses","volume":"68","author":"Austin","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: New guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: Results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-015-1086-2","article-title":"The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: A subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial","volume":"19","author":"Muto","year":"2015","journal-title":"Clin Exp Nephrol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0007342020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:41Z","timestamp":1786478561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0007342020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0007342020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2020-12-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}